Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMO 2055

Drug Profile

IMO 2055

Alternative Names: EMD 1201081; HYB-2055; IMO-2055; IMOxine; TLR9 immunomodulator

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Merck KGaA
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Highest Development Phases

  • Suspended Colorectal cancer; Non-small cell lung cancer
  • No development reported Cancer; Head and neck cancer
  • Discontinued Asthma; Renal cell carcinoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
  • 04 Aug 2015 No recent reports on development identified - Phase-II for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA, Belgium, Czech Republic, France, Hungary, United Kingdom, Slovakia and Poland (SC)
  • 02 Dec 2014 Final pharmacodynamics data from preclinical models of bladder, colon, and lung cancer released by Idera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top